{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-17T21:27:31.124728+00:00","company":{"ticker":"GTHP","cik":924515,"company_name":"GUIDED THERAPEUTICS INC"},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"equity_issuance","fact_key":"7dcf816224ecf5cf8f761b16feac78db0203bfbc","cik":924515,"ticker":"GTHP","company_name":"GUIDED THERAPEUTICS INC","filed_at":"2026-03-10T23:59:59+00:00","payload":{"action":"other","consideration_text":null,"effective_date":"2026-03-02","item_codes_triggered":["3.02"],"purchaser":"holders of Eligible Warrants","security_type":"common_stock","shares_text":"4,825,000 shares"},"claim":"GUIDED THERAPEUTICS INC issued 4,825,000 shares of common stock to holders of Eligible Warrants.","evidence_excerpt":"on March 2, 2026, the Company issued an aggregate of 4,825,000 shares of Common Stock to holders of Eligible Warrants.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001477932-26-001252","anchor_url":"https://secwatch.observer/filing/0001477932-26-001252#claim-7dcf816224ecf5cf8f761b16feac78db0203bfbc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001252/0001477932-26-001252-index.htm"},{"fact_type":"executive_change","fact_key":"5cd25692ac","cik":924515,"ticker":"GTHP","company_name":"GUIDED THERAPEUTICS INC","filed_at":"2023-03-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-08","interim":false,"role":"Director","role_category":"director","successor_name":"Gene Cartwright","successor_named":true},"claim":"Alan Grujic was appointed as Director at GUIDED THERAPEUTICS INC.","evidence_excerpt":"the Board appointed Mr. Alan Grujic to replace Mr. Cartwright on the Board, effective March 8, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001477932-23-001383","anchor_url":"https://secwatch.observer/filing/0001477932-23-001383#claim-5cd25692ac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223001383/0001477932-23-001383-index.htm"},{"fact_type":"executive_change","fact_key":"aed0fa59f9","cik":924515,"ticker":"GTHP","company_name":"GUIDED THERAPEUTICS INC","filed_at":"2023-03-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-06","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Mark Faupel was appointed as President and Chief Executive Officer at GUIDED THERAPEUTICS INC.","evidence_excerpt":"the Board appointed Dr. Mark Faupel, Ph.D., 67, the Company’s Chief Operating Officer since December 2016, to replace Mr. Cartwright as the Company’s President and Chief Executive Officer, effective as of March 6, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001477932-23-001383","anchor_url":"https://secwatch.observer/filing/0001477932-23-001383#claim-aed0fa59f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223001383/0001477932-23-001383-index.htm"},{"fact_type":"executive_change","fact_key":"63d9b63eb2","cik":924515,"ticker":"GTHP","company_name":"GUIDED THERAPEUTICS INC","filed_at":"2023-03-09T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2023-03-03","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Mark Faupel","successor_named":true},"claim":"Gene Cartwright retired as President and Chief Executive Officer at GUIDED THERAPEUTICS INC.","evidence_excerpt":"Dr. Gene Cartwright notified the Board of Directors (the “ Board ”) of Guided Therapeutics, Inc. (the “ Company ”) of his intent to retire from his position as President and Chief Executive Officer of the Company and as a member of the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001477932-23-001383","anchor_url":"https://secwatch.observer/filing/0001477932-23-001383#claim-63d9b63eb2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223001383/0001477932-23-001383-index.htm"}]}